And the cancer cells viability was investigated by CCK-8 assay. As shown in Fig. , the viability of the EH@Ag2S-treated group was evidently decrease compared with the PBS-treated group even stronger than the antibody-treated group. The results indicated that EH@Ag2S restored the T cell antitumor response. In general, all the results demonstrated that EH@Ag2S could provide robust tumor inhibition and achieve tumor therapy synergistically.